ResearchSafe

CJC-1295 (CJC-1295 (Modified GRF 1-29))

Category: Growth Hormone. Status: Research compound.

A synthetic GHRH analog with 4 amino acid substitutions for stability. Often combined with DAC for extended half-life or used without DAC for pulsatile release.

How it works

Binds GHRH receptors on anterior pituitary somatotrophs, stimulating cAMP-dependent GH synthesis and pulsatile release.

Key facts

  • Molecular weight: 3,368 Da (without DAC)
  • Half-life: 30 minutes (no DAC) / 8 days (with DAC)
  • Bioavailability: High (SubQ)
  • Storage: Lyophilized: -20°C. Reconstituted: 2-8°C for 21 days.

Dosing overview

  • Typical dose: 100-300 mcg
  • Frequency: 1-3x daily (no-DAC)
  • Duration: 8-16 weeks
  • Route: Subcutaneous injection

Protocol notes

  • No-DAC (Mod GRF 1-29) is almost always paired with a GHRP (ipamorelin/GHRP-2) for a synergistic GH pulse.
  • Typical: 100 mcg CJC + 100-200 mcg ipamorelin, injected together.
  • Dose 1-3x daily: pre-bed is the highest-value pulse; pre-workout and fasted-morning are common adds.

Reported benefits

  • Increased GH production
  • Improved body composition
  • Enhanced recovery
  • Better sleep quality
  • Anti-aging effects
  • Fat loss

Possible side effects

  • Flushing
  • Headache
  • Water retention
  • Tingling/numbness
  • Increased hunger

Research

  • CJC-1295 effects on GH secretion in healthy adults (2020): Increased mean GH levels by 200-1000% and IGF-1 by 50-70% sustained over 6-14 days after single injection.
  • Pulsatile vs sustained GH release with GHRH analogs (2019): Non-DAC CJC-1295 preserved physiological GH pulsatility while achieving 2-10x baseline elevation.

Compare CJC-1295

Community discussions about CJC-1295

Research and educational reference only. Not medical advice.